Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1201855

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

(Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet) Guglielmetti, Lorenzo; Günther, Gunar; Leu, Claude; Cirillo, Daniela; Duarte, Raquel; Garcia-Basteiro, Alberto L.; Goletti, Delia; Janković, Mateja; Kuksa, Liga; Maurer, Florian P. et al.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component // The European respiratory journal, 59 (2022), 5; 2200388, 3 doi:10.1183/13993003.00388-2022 (međunarodna recenzija, pismo uredniku, stručni)

CROSBI ID: 1201855 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Autori
Guglielmetti, Lorenzo ; Günther, Gunar ; Leu, Claude ; Cirillo, Daniela ; Duarte, Raquel ; Garcia-Basteiro, Alberto L. ; Goletti, Delia ; Janković, Mateja ; Kuksa, Liga ; Maurer, Florian P. ; Méchaï, Frédéric ; Tiberi, Simon ; van Leth, Frank ; Veziris, Nicolas ; Lange, Christoph

Kolaboracija
Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet

Izvornik
The European respiratory journal (0903-1936) 59 (2022), 5; 2200388, 3

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, stručni

Ključne riječi
rifapentine, tuberculosis

Sažetak
Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Zagreb,
Klinika za plućne bolesti "Jordanovac",
Klinički bolnički centar Zagreb

Profili:

Avatar Url Mateja Janković Makek (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

(Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet) Guglielmetti, Lorenzo; Günther, Gunar; Leu, Claude; Cirillo, Daniela; Duarte, Raquel; Garcia-Basteiro, Alberto L.; Goletti, Delia; Janković, Mateja; Kuksa, Liga; Maurer, Florian P. et al.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component // The European respiratory journal, 59 (2022), 5; 2200388, 3 doi:10.1183/13993003.00388-2022 (međunarodna recenzija, pismo uredniku, stručni)
(Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet) (Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and the Tuberculosis Network European Trials group (TBnet) Guglielmetti, Lorenzo, Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A., Goletti, D., Janković, M., Kuksa, L. & Maurer, F. (2022) Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. The European respiratory journal, 59 (5), 2200388, 3 doi:10.1183/13993003.00388-2022.
@article{article, author = {Guglielmetti, Lorenzo and G\"{u}nther, Gunar and Leu, Claude and Cirillo, Daniela and Duarte, Raquel and Garcia-Basteiro, Alberto L. and Goletti, Delia and Jankovi\'{c}, Mateja and Kuksa, Liga and Maurer, Florian P. and M\'{e}cha\"{\i}, Fr\'{e}d\'{e}ric and Tiberi, Simon and van Leth, Frank and Veziris, Nicolas and Lange, Christoph}, year = {2022}, pages = {3}, DOI = {10.1183/13993003.00388-2022}, chapter = {2200388}, keywords = {rifapentine, tuberculosis}, journal = {The European respiratory journal}, doi = {10.1183/13993003.00388-2022}, volume = {59}, number = {5}, issn = {0903-1936}, title = {Rifapentine access in Europe: growing concerns over key tuberculosis treatment component}, keyword = {rifapentine, tuberculosis}, chapternumber = {2200388} }
@article{article, author = {Guglielmetti, Lorenzo and G\"{u}nther, Gunar and Leu, Claude and Cirillo, Daniela and Duarte, Raquel and Garcia-Basteiro, Alberto L. and Goletti, Delia and Jankovi\'{c}, Mateja and Kuksa, Liga and Maurer, Florian P. and M\'{e}cha\"{\i}, Fr\'{e}d\'{e}ric and Tiberi, Simon and van Leth, Frank and Veziris, Nicolas and Lange, Christoph}, year = {2022}, pages = {3}, DOI = {10.1183/13993003.00388-2022}, chapter = {2200388}, keywords = {rifapentine, tuberculosis}, journal = {The European respiratory journal}, doi = {10.1183/13993003.00388-2022}, volume = {59}, number = {5}, issn = {0903-1936}, title = {Rifapentine access in Europe: growing concerns over key tuberculosis treatment component}, keyword = {rifapentine, tuberculosis}, chapternumber = {2200388} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.